Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.

Gunjur, Ashray; Balasubramanian, Adithya; Hafeez, Umbreen; Menon, Siddharth; Cher, Lawrence; Parakh, Sagun; Gan, Hui Kong

Gunjur, Ashray; Balasubramanian, Adithya; Hafeez, Umbreen; Menon, Siddharth; Cher, Lawrence; Parakh, Sagun; Gan, Hui Kong.

Afiliação

Gunjur A; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK.
Balasubramanian A; Department of Medical Oncology, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Hafeez U; Department of Medical Oncology, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Menon S; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia.
Cher L; Department of Medical Oncology, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Parakh S; Olivia Newton-John Cancer Research Institute, Austin Hospital, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Gan HK; La Trobe University School of Cancer Medicine, 145 Studley Road, Heidelberg, VIC, 3084, Australia.

J Neurooncol ; 159(3): 539-549, 2022 Sep.

Article em En | MEDLINE | ID: mdl-35933567

Assuntos

Glioblastoma; Adulto; Glioblastoma/terapia; Humanos

Palavras-chave

Drug development; Glioblastoma; Phase 1 trials; Preclinical models

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glioblastoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glioblastoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article